The effectiveness of the intermediate and therapeutic doses of enoxaparin in COVID-19 patients: A comparative study of factor Xa inhibition
Abstract
Background: Management of anticoagulant therapy in COVID-19 patients is a critical role. Low Molecular Weight Heparin (LMWH) thromboprophylaxis is already recommended and anti-Factor Xa (anti-FXa) monitoring has been used to titrate LMWH doses.
Methods: Through a cross-sectional study, we evaluated anti-FXa activity in patients admitted to ICU, receiving intermediate dose (30, 40, 50mg, subcutaneously (SC), twice daily) or therapeutic dose (1 mg/kg, SC, Q12h) of enoxaparin to find whether the patients of these two groups achieve anti-FXa levels in the accepted thromboprophylaxis range.
Results: The occurrence of DVT was 26% in the therapeutic dose and 17% in the intermediate-dose group. D-dimer values were nearly 3.5-fold higher in those who received a therapeutic-dose of anticoagulants than in those who received intermediate dose thromboprophylaxis. Patients in the therapeutic dose group had significantly higher IL-6 levels (p≤0.001). More than one-third of the patients in the therapeutic dose group (n = 8; 42.18%) and approximately half of the patients in the intermediate-dose group (n = 12; 52.2%) achieved the target range level of anti-FXa. Patients who received therapeutic doses were more likely to have anti-FXa levels above the expected range (47.4 Vs 13% in the intermediate dose group. P
S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Comments (0)